Pitt-Ohio State Clinical Trials Unit Administrative Supplement
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 3UM1AI069494-14S1
Grant search
Key facts
Disease
COVID-19Start & end year
2020.02021.0Known Financial Commitments (USD)
$533,144Funder
National Institutes of Health (NIH)Principal Investigator
. SUSAN KOLETARResearch Location
United States of AmericaLead Research Institution
UNIVERSITY OF PITTSBURGH AT PITTSBURGHResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Diagnostics
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Unspecified
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
The University of Pittsburgh Virology Specialty Laboratory will test various samples provided (nasopharyngeal swabs, throat swabs, and saliva) using EUA approved testing platforms from ThermoFisher and Hologic for patients testing for SARS-CoV-2 to increase the United States testing capacity. Testing volume will depend on sample delivery and test kit availability. Capacity will initially approximate 25-50 samples today, ramping up to 100-200 per day with a sufficient supply chain for reagents. The Ohio State University Medical Center's Clinical Laboratories are significantly increasing their testing capacity using multiple platforms for PCR and serologic testing (e.g. CDC, DiaSorin, Abbott to name a few). Using the Medical Center's CLIA-certified testing venues, we propose to develop a protocol to identify, test and obtain clinical history from defined populations who are not in the top tier for priority testing.